Glioma Clinical Trials

Find Glioma Clinical Trials Near You

Adaptive Radiotherapy Based on Multi-Parametric Diffusion- and Perfusion-weighted Magnetic Resonance Imaging in Patients With Newly Diagnosed High-Grade Glioma

Status: Active_not_recruiting
Location: See location...
Study Type: Observational
SUMMARY

The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histopathologically proven diagnosis of glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma

• History and physical examination within 28 days prior to enrollment

• Karnofsky performance status 70 or greater

• Age 18 years or greater

• Negative pregnancy test for females of childbearing potential before 1st research MRI, performed in accordance to institutional guidelines.

• Plan to receive standard of care 59.4-60 Gy in 30-33 fractions of radiotherapy. Glioblastoma patients over 65 year-old can receive standard of care hypofractionated radiotherapy including 40 Gy in 15 fractions.

Locations
United States
New York
Columbia University Irving Medical Center/NYPH
New York
Time Frame
Start Date: 2024-01-30
Completion Date: 2027-12
Participants
Target number of participants: 20
Treatments
Patients with primary high-grade glioma
Patients will receive standard of care radiotherapy over 30-33 once-daily fractions. Subjects receiving hypofractionated radiotherapy will receive radiotherapy per standard of care over 15 once-daily fractions.
Sponsors
Leads: Columbia University
Collaborators: Varian Medical Systems

This content was sourced from clinicaltrials.gov